FrancophonIA/ELRC3.0 huggingface dataset:
English: A/Michigan/45/2015 (H1N1)pdm09 - like strain (A/Michigan/45/2015, NYMC X-275) ................................................................................................................................ 15 micrograms HA** A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B) ................................................................................................................................ 15 micrograms HA** B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) ....................... 15 micrograms HA**
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Gripiviiruse (inaktiveeritud, purustatud) järgmised tüved*: A/Michigan/45/2015 (H1N1)pdm09 - sarnane tüvi (A/Michigan/45/2015, NYMC X-275) ............................................................................................................................. 15 mikrogrammi HA** A/Hong Kong/4801/2014 (H3N2) - sarnane tüvi (A/Hong Kong/4801/2014, NYMC X-263B) ............................................................................................................................. 15 mikrogrammi HA** B/Brisbane/60/2008 - sarnane tüvi (B/Brisbane/60/2008, metsikut tüüpi) ......... 15 mikrogrammi HA**
English: INTANZA 15 microgram/strain suspension for injection Influenza vaccine (split virion, inactivated)
Estonian: INTANZA 15 mikrogrammi/tüvele süstesuspensioon Gripivaktsiin (inaktiveeritud purustatud viirus)
English: INTANZA is a suspension for injection in a pre-filled syringe of 0.1 ml with a Micro-Injection
Estonian: INTANZA on süstelahus eeltäidetud 0,1 ml mikrosüste süsteemiga süstelis.
English: INTANZA 15 µg/strain 2017/2018 Influenza vaccine
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE INTANZA 15 µg/tüvele 2017/2018
English: In a pivotal randomised comparative phase III trial, 2,606 subjects over 60 years of age received 0.1 ml of INTANZA by intradermal route and 1,089 subjects over 60 years of age received 0.5 ml of a trivalent inactivated influenza vaccine administered by intramuscular route.
Estonian: Pöördelisel randomiseeritud võrdleval III faasi uuringul manustati 2 606-le uuringus osalejale, vanuses üle 60. eluaasta, 0,1 ml INTANZA'd nahasiseselt ja 1 089-le uuringus osalejale, vanuses üle 60. eluaasta, 0,5 ml trivalentset inaktiveeritud gripivaktsiini lihasesiseselt.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE /MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 24. veebruar 2009
English: ** Seroconversion = negative pre-vaccination HI titre and post vaccination HI titre ≥ 40, Significant increase = positive pre-vaccination HI titre and at least a 4-fold increase in post-vaccination HI titre GMTR: Geometric mean titre ratio of individual (post-/pre-vaccination titre).
Estonian: märkimisväärne tõus = positiivsed vaktsineerimiseelsed HI tiitrid ja vähemalt 4-kordselt suurenenud vaktsineerimisjärgne HI tiiter
English: Talk to your doctor, pharmacist or nurse before using INTANZA.
Estonian: Arst või meditsiiniõde manustab teile INTANZA'd.
English: Sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium dihydrogen
Estonian: Naatriumkloriid, kaaliumkloriid, dinaatriumfosfaatdihüdraat, kaaliumdivesinikfosfaat, süstevesi
English: Flange
Estonian: Flanš
English: INTANZA will help to protect you against the three strains of virus contained in the vaccine, or other strains closely related to them.
Estonian: Peale INTANZA süsti saamist kujundab keha immuunsüsteem (organismi loomulik kaitse) välja INTANZA aitab kaitsta teid kolme vaktsiinis sisalduva viiruse tüve või neile sarnaste tüvede eest.
English: A/Michigan/45/2015 (H1N1)pdm09 - like strain A/Hong Kong/4801/2014 (H3N2) - like strain
Estonian: Toimeained on gripiviiruse (inaktiveeritud, purustatud) järgmised tüved*: A/Michigan/45/2015 (H1N1)pdm09 - sarnane tüvi (A/Michigan/45/2015, NYMC X-275)
English: Paediatric population
Estonian: Gripivaktsiin
English: What INTANZA is and what it is used for
Estonian: Mis on INTANZA ja milleks seda kasutatakse INTANZA on vaktsiin.
English: INTANZA is at least as immunogenic as the comparator trivalent inactivated influenza vaccine administered by intramuscular route for each of the 3 influenza strains in subjects from 60 years of age and over.
Estonian: Vanuses üle 60. eluaasta uuringus osalejatel on INTANZA kõigi 3 gripitüve puhul vähemalt sama immunogeenne kui võrreldav trivalentne inaktiveeritud, lihasesiseselt manustatud gripivaktsiin.
English: In case of presence of liquid at the injection site after vaccine administration, re-vaccination is not required.
Estonian: Revaktsineerimine ei ole nõutav, kui pärast vaktsiini manustamist on süstimise kohal vedelikku.
English: Pack of 1 or 10 or 20 pre-filled syringe(s) with a Micro-Injection System
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Pakendid 1 või 10 või 20 eeltäidetud mikrosüste süsteemiga süsteliga
English: - Other vaccines: INTANZA can be given at the same time as other vaccines by using separate limbs.
Estonian: 4.5 Koostoimed teiste ravimitega ja muud koostoimed INTANZA'd võib manustada samaaegselt teiste vaktsiinidega.
English: Vasculitis associated in very rare cases with transient renal involvement
Estonian: Vaskuliit väga harvadel juhtudel koos lühiajalise neerude kahjustusega Võimalikest kõrvaltoimetest teavitamine
English: B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) .................... 15 micrograms HA**
Estonian: B A/Wisconsin/ 67/2005 B/Malaysia/ 2506/2004
English: Plunger
Estonian: Immunogeensus
English: 4.5 Interaction with other medicinal products and other forms of interaction
Estonian: Muud vaktsiinid või ravimid ja INTANZA
English: MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE
Estonian: BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST
English: EXPIRY DATE
Estonian: Sanofi AB
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom26 June 2017
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom26.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/118)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/118) tulemused
English: The applicants and marketing authorisation holders concerned by the referral procedure submitted proprietary data and scientific references on efficacy, antimicrobial resistance and environmental risk.
Estonian: Esildismenetlusega hõlmatud müügilubade taotlejad ja hoidjad esitasid ettevõttesisesed andmed ja teaduslikud viited efektiivsuse, antimikroobse resistentsuse ja keskkonnariski kohta.
English: The European Commission issued a decision on 26 June 2017 and Member States may defer the withdrawal of the marketing authorisations for up to five years from this date, if they consider that immediate action may have adverse impact in their territory given the lack of availability of alternatives and the change required in pig farming practices.
Estonian: Euroopa Komisjon väljastas otsuse 26. juunil 2017 ja liikmesriigid võivad edasi lükata müügilubade tühistamist kuni viie aasta jooksul alates sellest kuupäevast, kui kohene toimimine võib liikmesriigi hinnangul omada riigi territooriumil kahjulikku mõju, arvestades alternatiivsete meetodite puudumist ja seakasvatustavade muutmise vajadust.
English: Different indications and dosages are currently recommended, but zinc oxide is mainly used in the feed at a dosage of 100 mg per kg body weight per day for 14 consecutive days, which equates to 2500 ppm zinc in feed.
Estonian: Praegused soovitused hõlmavad erinevaid näidustusi ja annuseid, kuid peamiselt kasutatakse tsinkoksiidi söödas annuses 100 mg kehamassi kg kohta ööpäevas 14 järjestikusel päeval, seega 2500 miljondikku osa tsinki söödas.
English: Why were orally-administered veterinary medicinal products containing zinc oxide reviewed?
Estonian: Miks vaadati läbi suukaudselt manustatavad tsinkoksiidi sisaldavad veterinaarravimid?
English: Zinc oxide is an inorganic compound and is known to be relatively poorly absorbed.
Estonian: Tsinkoksiid on anorgaaniline ühend, mis teadaolevalt imendub halvasti.
English: On 16 March 2017, the European Medicines Agency (the Agency) completed a review of the safety and effectiveness of veterinary medicinal products containing zinc oxide to be administered orally to food-producing species.
Estonian: 16. märtsil 2017 lõpetas Euroopa Ravimiamet (EMA) toiduloomadele suukaudseks manustamiseks ette nähtud tsinkoksiidi sisaldavate veterinaarravimite ohutuse ja efektiivsuse läbivaatamise.
English: In May 2015, following a referral procedure (EMEA/V/A/108) under Article 33(4) of Directive 2001/82/EC for Gutal 1000 g/kg premix for medicated feeding stuff for piglets1, the CVMP identified a risk to the environment due to accumulation of zinc.
Estonian: 2015. aasta mais, pärast direktiivi 2001/82/EÜ artikli 33 lõike 4 kohast esildismenetlust Gutal 1000 g/kg põrsaste ravimsööda eelsegu kohta (EMEA/V/A/108),1 tuvastas veterinaarravimite komitee tsingi kuhjumisest tingitud keskkonnariski.
English: The CVMP acknowledged that there is a risk of co-selection for resistance (the selection of multiple antimicrobial resistance genes by an antimicrobial) associated with the use of zinc oxide but that, at the present time, such risk is not quantifiable.
Estonian: Veterinaarravimite komitee märkis, et tsinkoksiidi kasutamisega on seotud resistentsuse kaasselektsiooni (antimikroobse aine toimel esinev mitme antimikroobse aine resistentsuse geenide väljaselekteerumine) risk, mida praegu ei ole võimalik veel kvantifitseerida.
English: What is zinc oxide?
Estonian: Mis on tsinkoksiid?
English: Nevertheless, in February 2016, due to remaining concerns related to the risk to the environment and the potential increase of prevalence of antibiotic resistant bacteria from the use of products containing zinc oxide, the Netherlands and France initiated a referral procedure under Article 35 of Directive 2001/82/EC for all orally-administered veterinary medicinal products containing zinc oxide and requested the CVMP to review all available data and to evaluate the overall benefit-risk balance of the products concerned.
Estonian: suurenemise võimalust, algatasid Madalmaad ja Prantsusmaa 2016. aasta veebruaris direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse kõigi tsinkoksiidi sisaldavate suukaudselt manustatavate veterinaarravimite kohta ja taotlesid veterinaarravimite komiteelt kõigi olemasolevate andmete läbivaatamist ja asjaomaste ravimpreparaatide üldise kasulikkuse ja riski tasakaalu hindamist.
English: Effective measures to manage the accumulation of zinc in the environment were not identified and, as a result, the CVMP recommended the refusal of the granting of the marketing authorisations and the withdrawal of the existing marketing authorisations for veterinary medicinal products containing zinc oxide.
Estonian: Efektiivseid meetmeid tsingi keskkonda kuhjumise ennetamiseks tuvastatud ei ole ja seega soovitas veterinaarravimite komitee keelduda müügilubade andmisest tsinkoksiidi sisaldavatele veterinaarravimitele ja tühistada kehtivad müügiload.
English: The CVMP recommended the refusal of the granting of the marketing authorisations and the withdrawal of the existing marketing authorisations for veterinary medicinal products containing zinc oxide.
Estonian: Veterinaarravimite komitee soovitas keelduda müügilubade andmisest ja peatada tsinkoksiidi sisaldavate veterinaarravimite kehtivad müügiload.
English: The CVMP considered that there is some uncertainty associated with the calculated risks for some environmental compartments and recommended various risk mitigation measures, which were anticipated to reduce the accumulation of zinc in the environment.
Estonian: Veterinaarravimite komitee oli arvamusel, et osade keskkonnakomponentide kohta arvutatud riskid ei ole täiesti täpsed ja soovitas rakendada mitmesuguseid riskide vähendamise abinõusid, mis eeldatavalt vähendavad tsingi kuhjumist keskkonda.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the overall benefit-risk balance for veterinary medicinal products containing zinc oxide to be administered orally to pigs is negative, as the benefits of zinc oxide for the prevention of diarrhoea in pigs do not outweigh the risks for the environment.
Estonian: Ameti veterinaarravimite komitee otsustas, et suukaudselt sigadele manustatavate tsinkoksiidi sisaldavate veterinaarravimite üldine kasulikkuse ja riski tasakaal on negatiivne, sest tsinkoksiidist saadav kasu põrsaste kõhulahtisuse ennetamisel ei kaalu üles keskkonnariske.
English: EMA/394961/2017
Estonian: juuni 2017
English: Based on the evaluation of the currently-available data, the CVMP concluded that the overall benefitrisk balance for veterinary medicinal products containing zinc oxide to be administered orally to pigs is negative, as the benefits of zinc oxide for the prevention of diarrhoea in pigs do not outweigh the risks for the environment.
Estonian: Olemasolevate andmete hindamisele tuginedes järeldas veterinaarravimite komitee 2016. aasta detsembri koosolekul, et toiduloomadele suukaudselt manustatavate tsinki sisaldavate veterinaarravimite üldine kasulikkuse ja riski tasakaal on negatiivne, sest tsinkoksiidist saadav kasu põrsaste kõhulahtisuse ennetamisel ei kaalu üles keskkonnariske.
English: Questions and answers on veterinary medicinal products containing zinc oxide to be administered orally to food-producing species
Estonian: Sellele vaatamata võttes arvesse keskkonnariskiga seotud lahendamata küsimusi ja tsinkoksiidi sisaldavate toodete kasutamisest tingitud antibiootikumidele resistentsete bakterite levimuse
English: It is given once a day for five days.
Estonian: Easoticit antakse üks kord päevas viie päeva jooksul.
English: One large field trial was conducted in different centres throughout Europe.
Estonian: Viidi läbi üks suur väliuuring eri keskustes üle kogu Euroopa.
English: The medicine was well tolerated.
Estonian: Ravimit taluti hästi.
English: This is usually temporary and happens primarily in older dogs.
Estonian: See on tavaliselt ajutine ja esineb eelkõige vanematel koertel.
English: It is available in a 10 ml bottle.
Estonian: Seda turustatakse 10 ml pudelis.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Easotic to Virbac S.A. on 20/11/2008.
Estonian: Euroopa Komisjon väljastas Easotici müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Virbac S.A. 20. november 2008.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EASOTIC EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE EASOTIC Kokkuvõte üldsusele
English: The use of ear preparations may be associated with damage to hearing.
Estonian: Kõrvapreparaatide kasutamisega võib kaasneda kuulmiskahjustus.
English: The inside of the ear should be cleaned and dried before treatment and any excess hair cut away.
Estonian: Enne ravi peab kõrva sisemus olema puhas ja kuiv ning liigsed karvad peab eemaldama.
English: This summary was last updated in November 2008.
Estonian: Kokkuvõtte viimane uuendus: 11-2008.
English: What is Easotic?
Estonian: Mis on Easotic?
English: The dose is 1 ml, which is given directly into the ear by one activation of the pump supplied with the bottle.
Estonian: Ravimi annus on 1 ml, mis manustatakse pudeliga turustatava pumba ühekordse aktiveerimise abil vahetult kõrva.
English: Other information about Easotic:
Estonian: Muu teave Easotici kohta
English: Easotic has been studied in dogs in both laboratory and field trials.
Estonian: Easoticit uuriti koertel nii laboratooriumi- kui väliuuringutes.
English: If a person accidentally takes the medicine or eye irritation occurs, seek medical advice immediately and show the package leaflet or the label to a doctor.
Estonian: Kui inimene peaks seda ravimit juhuslikult alla neelama või kui tekib silmaärritus, tuleb pöörduda kohe arsti poole ning näidata pakendi infolehte või etiketti.
English: This stops the bacteria growing, resulting in their death.
Estonian: Ta peatab bakterite kasvu, mille tulemusena bakterid hävivad.
English: Easotic contains three active substances: hydrocortisone aceponate, miconazole nitrate and gentamicin sulphate.
Estonian: Easotic sisaldab kolme toimeainet: hüdrokortisoonatseponaati, mikonasoolnitraati ja gentamütsiinsulfaati.
English: Gentamicin sulphate is an antibiotic that belongs to the group aminoglycosides.
Estonian: Gentamütsiinsulfaat on aminoglükosiidide rühma kuuluv antibiootikum.
English: Mild reddening of the ear has been seen in around 2% of dogs.
Estonian: Ligikaudu 2%-l koertest on täheldatud kerget nahapunetust kõrval.
English: In the study, the effectiveness of Easotic was compared with that of ear drops containing three similar active substances in dogs with acute or recurrent bacterial or fungal ear infections.
Estonian: Uuringus võrreldi Easotici efektiivsust kolme samalaadset toimeainet sisaldavate kõrvatilkade efektiivsusega ägeda või korduva kõrva bakteriaalse või seeninfektsiooniga koertel.
English: Easotic is used to treat dogs that suffer from acute or recurrent episodes of ear infections (otitis externa).
Estonian: Easoticit kasutatakse koertel ägeda või korduva kõrvainfektsiooni (otitis externa) raviks.
English: If accidental skin or eye contact occurs, wash immediately with lots of water.
Estonian: Juhuslikul nahale või silma sattumisel tuleb seda kohta kohe loputada rohke veega.
English: It acts by preventing bacteria making proteins.
Estonian: Ta pärsib valkude teket bakterites.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Easotic exceed the risks for the treatment of acute otitis externa, and acute exacerbation of recurrent otitis externa associated with bacteria susceptible to gentamicin and fungi susceptible to miconazole in particular Malassezia pachydermatis, and recommended that Easotic be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Easotici kasulikkus gentamütsiinile tundlike bakterite ja mikonasoolile eelkõige poolt põhjustatud ägeda otitis externa ja otitis externa korduvate ägenemiste ravis ületab ravimiga seotud ohud, ning soovitas anda Easoticile müügloa.
English: Why has Easotic been approved?
Estonian: Miks Easotic heaks kiideti?
English: For a full list of all side-effects reported with Easotic, see the Package Leaflet.
Estonian: Easotici kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Easotic must not be used in dogs that may be allergic to the active substances or any of the other ingredients, if the eardrum is perforated, at the same time as other medicines that can harm the ear, or in dogs with a parasite infection called generalised demodecosis (mange).
Estonian: Easoticit ei tohi kasutada koertel, kes võivad olla ravimi toimeainete või selle ravimi mis tahes muu koostisaine suhtes allergilised ega koertel, kelle trummikile on perforeeritud või kellel on parasiitnakkus generaliseerunud demodekoos.
English: It is an ear drop suspension for dogs, that is white in colour.
Estonian: Easotic on valget värvi kõrva manustatav suspensioon koertele.
English: Miconazole nitrate is an antifungal that works by preventing the formation of ergosterol, which is an important part of fungal cell walls.
Estonian: Mikonasoolnitraat on seenevastane ravim, mille toime seisneb seente rakumembraani olulise koostisaine ergosterooli moodustumise pärssimises.
English: How does Easotic work?
Estonian: Kuidas Easotic toimib?
English: What benefit has Easotic shown during the studies?
Estonian: Milles seisneb uuringute põhjal Easotici kasulikkus?
English: Hydrocortisone aceponate is a glucocorticosteroid, which is a type of substance that helps to reduce inflammation and itching.
Estonian: Hüdrokortisoonatseponaat on glükokortikosteroid, millel on põletikuvastane ja sügelust vähendav toime.
English: How has Easotic been studied?
Estonian: Kuidas Easoticit uuriti?
English: Two of the active substances in Easotic, miconazole nitrate and gentamicin sulphate, work against the cause of the infection, while the third one, hydrocortisone aceponate, works on the inflammation.
Estonian: Kaks Easotici toimeainet, mikonasoolnitraat ja gentamütsiinsulfaat, võitlevad infektsiooniga.
English: What is the risk associated with Easotic?
Estonian: Mis riskid kaasnevad Easotociga?
English: What is Easotic used for?
Estonian: Milleks Easoticit kasutatakse?
English: When used at the recommended dose for five days, Easotic was as effective as the comparator medicine in improving the symptoms of ear infection (redness, swelling, ear discharge and discomfort).
Estonian: Ägeda või korduva kõrvainfektsiooni sümptomite (punetus, turse, kõrvaeritised ja ebamugavustunne) leevendamisel koertel osutus ravi Easoticiga soovitatavas annuses viie päeva jooksul sama efektiivseks kui ravi võrdlusravimiga.
English: List of the name, pharmaceutical form, strength of the medicinal product, route of administration, marketing authorisation holder in the Member States
Estonian: Ravimite nimetuste, ravimvormide, ravimi tugevuse, manustamistee, müügiloa hoidja loetelu liikmesriikides
English: Austria implant, pre-filled syringe subcutaneous use
Estonian: Austria implantaat, süstlis
English: Annex I
Estonian: Ühendkuningriik
English: The European Medicines Agency decided that NexGard's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et NexGardi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: Other information about NexGard
Estonian: Muu teave NexGardi kohta
English: Further information on NexGard can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/NexGard.
Estonian: Lisateave NexGardi kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/NexGard.
English: NexGard received a marketing authorisation valid throughout the EU on 11 February 2014.
Estonian: NexGardi müügiluba, mis kehtib kogu Euroopa Liidus, anti 11. veebruaril 2014.
English: NexGard kills fleas within 8 hours and ticks within 48 hours.
Estonian: NexGard hävitab koertel kirbud 8 tunni jooksul ja puugid 48 tunni jooksul.
English: The effectiveness of NexGard was investigated in both laboratory and field studies.
Estonian: NexGardi efektiivsust uuriti labori- ja väliuuringutega.
English: NexGard (afoxolaner) EMA/783550/2013
Estonian: NexGard (afoksolaneer) EMA/783550/2013
English: NexGard (afoxolaner)
Estonian: NexGard (afoksolaneer)
English: The blister with the remaining chewable tablets should be returned into the carton.
Estonian: Ülejäänud närimistablettidega blister tuleb karpi tagasi panna.
English: Afoxolaner kills parasites by causing an over-stimulation of their nervous system.
Estonian: Afoksolaneer hävitab parasiidid, ülestimuleerides nende närvisüsteemi.
English: Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs' environment.
Estonian: Afoksolaneer hävitab kirbud enne munemist ja aitab sellega vähendada koerte ümbruskonna saastumist.
English: What is NexGard and what is it used for?
Estonian: Mis on NexGard ja milleks seda kasutatakse?
English: In order for the active substance to have an effect, fleas and ticks must attach to the skin and commence feeding on the dog's blood.
Estonian: Toimeainega kokkupuutumiseks peavad kirbud ja puugid kinnituma nahale ning imema koera verd.
English: For more information about using NexGard, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate NexGardiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: NexGard reduced the number of fleas and ticks by at least 98% and was at least as effective as a spoton medicine containing pyriprole (another medicine against fleas and ticks).
Estonian: NexGard vähendas kirpude ja puukide arvu vähemalt 98% võrra ning oli vähemalt sama efektiivne kui püriprooli sisaldav täpilahus (samuti kirpude ja puukide vastane ravim).